PDS Biotech rises after positive FDA meeting for cancer therapy

PDS Biotechnology

27/02/2023 15:29

** Shares of drug developer PDS Biotechnology Corp  PDSB.O 
rise 2% to $7.96 in early trade
    ** Company says the U.S. Food and Drug Administration (FDA),
in a meeting, has confirmed the contents for a study testing its
lead immunotherapy candidate, PDS0101, in combination with two
other drugs to treat a type of head and neck cancer
    ** The therapy tests PDS0101 in combination with another
experimental drug, PDS0301, and an FDA-approved immune
checkpoint inhibitor (ICI) - PDSB
    ** ICI is a type of drug that blocks proteins called
checkpoints made up of immune system cells, such as T cells, and
some cancer cells
    ** PDS0101 activates T cells against cancers testing
positive for human papilloma virus - PDSB  
    ** Including session moves, stock has risen ~32% in the past
12 months

 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com))